Higher rate of HBsAg loss after discontinuation of tenofovir than entecavir in patients with chronic hepatitis B.
Chien-Hung ChenCheng-Yuan PengTsung-Hui HuJing-Houng WangChao-Hung HungSheng-Nan LuPublished in: Alimentary pharmacology & therapeutics (2023)
Patients who discontinued TDF had significantly higher rates of HBsAg loss than patients who discontinued entecavir, especially among the subgroups without HBV relapse after cessation of therapy.
Keyphrases